Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.69
LFVN's Cash to Debt is ranked higher than
55% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.05 vs. LFVN: 0.69 )
LFVN' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: 0.69

Equity to Asset 0.07
LFVN's Equity to Asset is ranked lower than
54% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. LFVN: 0.07 )
LFVN' s 10-Year Equity to Asset Range
Min: -2.6   Max: 0.93
Current: 0.07

-2.6
0.93
Interest Coverage 6.12
LFVN's Interest Coverage is ranked lower than
51% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. LFVN: 6.12 )
LFVN' s 10-Year Interest Coverage Range
Min: 0.62   Max: 9999.99
Current: 6.12

0.62
9999.99
F-Score: 6
Z-Score: 3.91
M-Score: -2.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 9.09
LFVN's Operating margin (%) is ranked higher than
82% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. LFVN: 9.09 )
LFVN' s 10-Year Operating margin (%) Range
Min: -188.48   Max: 17
Current: 9.09

-188.48
17
Net-margin (%) 5.32
LFVN's Net-margin (%) is ranked higher than
78% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. LFVN: 5.32 )
LFVN' s 10-Year Net-margin (%) Range
Min: -247.32   Max: 9.88
Current: 5.32

-247.32
9.88
ROE (%) 75.69
LFVN's ROE (%) is ranked higher than
99% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. LFVN: 75.69 )
LFVN' s 10-Year ROE (%) Range
Min: -118.8   Max: 333.62
Current: 75.69

-118.8
333.62
ROA (%) 19.12
LFVN's ROA (%) is ranked higher than
96% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.28 vs. LFVN: 19.12 )
LFVN' s 10-Year ROA (%) Range
Min: -542.48   Max: 43.73
Current: 19.12

-542.48
43.73
ROC (Joel Greenblatt) (%) 291.45
LFVN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. LFVN: 291.45 )
LFVN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4604.72   Max: 1928.72
Current: 291.45

-4604.72
1928.72
Revenue Growth (%) 53.60
LFVN's Revenue Growth (%) is ranked higher than
99% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. LFVN: 53.60 )
LFVN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 120.4
Current: 53.6

0
120.4
» LFVN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

LFVN Guru Trades in Q3 2013

Joel Greenblatt 208,400 sh (-53.7%)
» More
Q4 2013

LFVN Guru Trades in Q4 2013

Steven Cohen 23,600 sh (New)
Joel Greenblatt Sold Out
» More
Q1 2014

LFVN Guru Trades in Q1 2014

HOTCHKIS & WILEY 13,571 sh (New)
Jim Simons 848,391 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

LFVN Guru Trades in Q2 2014

George Soros 53,600 sh (New)
Jim Simons 1,274,097 sh (+50.18%)
HOTCHKIS & WILEY 13,571 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with LFVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 New Buy$1.23 - $1.48 $ 1.2-11%53600
Joel Greenblatt 2013-12-31 Sold Out 0.02%$1.505 - $2.59 $ 1.2-40%0
Joel Greenblatt 2013-09-30 Reduce -53.7%0.02%$2.17 - $2.64 $ 1.2-51%208400
Arnold Van Den Berg 2013-06-30 Sold Out 0.04%$2.05 - $2.44 $ 1.2-48%0
Joel Greenblatt 2013-03-31 New Buy0.05%$2.16 - $2.9 $ 1.2-51%446875
Arnold Van Den Berg 2012-12-31 Add 221.09%0.03%$1.73 - $3.38 $ 1.2-56%170180
Arnold Van Den Berg 2012-06-30 Reduce -27.4%0.01%$2.59 - $3.83 $ 1.2-63%53000
Arnold Van Den Berg 2012-03-31 Reduce -29.13%$1.7 - $56.31 $ 1.2-84%73000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 11.50
LFVN's P/E(ttm) is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LFVN: 11.50 )
LFVN' s 10-Year P/E(ttm) Range
Min: 11.76   Max: 55
Current: 11.5

11.76
55
P/B 29.25
LFVN's P/B is ranked higher than
51% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. LFVN: 29.25 )
LFVN' s 10-Year P/B Range
Min: 0.77   Max: 50.67
Current: 29.25

0.77
50.67
P/S 0.63
LFVN's P/S is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.15 vs. LFVN: 0.63 )
LFVN' s 10-Year P/S Range
Min: 0.62   Max: 153.8
Current: 0.63

0.62
153.8
PFCF 13.00
LFVN's PFCF is ranked higher than
97% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LFVN: 13.00 )
LFVN' s 10-Year PFCF Range
Min: 10   Max: 162.5
Current: 13

10
162.5
EV-to-EBIT 6.76
LFVN's EV-to-EBIT is ranked higher than
97% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. LFVN: 6.76 )
LFVN' s 10-Year EV-to-EBIT Range
Min: 7   Max: 93.4
Current: 6.76

7
93.4
Current Ratio 1.76
LFVN's Current Ratio is ranked higher than
59% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. LFVN: 1.76 )
LFVN' s 10-Year Current Ratio Range
Min: 0.14   Max: 39
Current: 1.76

0.14
39
Quick Ratio 1.37
LFVN's Quick Ratio is ranked higher than
56% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. LFVN: 1.37 )
LFVN' s 10-Year Quick Ratio Range
Min: 0.14   Max: 39
Current: 1.37

0.14
39

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 58.50
LFVN's Price/Tangible Book is ranked higher than
57% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.22 vs. LFVN: 58.50 )
LFVN' s 10-Year Price/Tangible Book Range
Min: 6.25   Max: 67.5
Current: 58.5

6.25
67.5
Price/DCF (Projected) 1.74
LFVN's Price/DCF (Projected) is ranked higher than
86% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LFVN: 1.74 )
LFVN' s 10-Year Price/DCF (Projected) Range
Min: 2.01   Max: 59.38
Current: 1.74

2.01
59.38
Price/Median PS Value 0.28
LFVN's Price/Median PS Value is ranked higher than
97% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. LFVN: 0.28 )
LFVN' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 43.18
Current: 0.28

0.32
43.18
Price/Graham Number 5.32
LFVN's Price/Graham Number is ranked higher than
77% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LFVN: 5.32 )
LFVN' s 10-Year Price/Graham Number Range
Min: 3.63   Max: 6.14
Current: 5.32

3.63
6.14
Earnings Yield (Greenblatt) 14.80
LFVN's Earnings Yield (Greenblatt) is ranked higher than
93% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. LFVN: 14.80 )
LFVN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.1   Max: 14.3
Current: 14.8

1.1
14.3
Forward Rate of Return (Yacktman) -8.12
LFVN's Forward Rate of Return (Yacktman) is ranked higher than
61% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.98 vs. LFVN: -8.12 )
LFVN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -9.5   Max: 30
Current: -8.12

-9.5
30

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:L2T.Germany
Lifevantage Corporation was founded in 2003. It is a science based nutraceutical company dedicated to helping people achieve healthy living through a combination of a compelling business opportunity and scientifically validated products, including its patented dietary supplement Protandim(r), the Nrf2 Synergizer(r). LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. Protandim is a daily dietary supplement that combats oxidative stress through Nrf2 activation. Oxidative stress is inevitable for everyone. Protandim significantly reduces oxidative stress through Nrf2 activation. Nrf2 regulates survival genes. Comprised of natural plant ingredients, Protandim is a patented, science-based formula that has been researched, tested and validated by renowned universities and institutions. It is the only supplement clinically proven to reduce oxidative stress in humans by an average of 40 percent in 30 days. Protandim activates Nrf2, which communicates with cells, instructing them to do what they're already designed to do: up-regulate "survival genes," genes that enable cells to survive in the face of stress from free radicals and other oxidants, and down-regulate other genes that promote inflammation and fibrosis to help the body function at an optimal level. TrueScience Anti-Aging Cream provides the latest skin care technology. It targets the causes of aging, not just the signs. Its powerful anti-wrinkle formula boosts six skin-rebuilding essentials and contains the 11 ingredients described as the most effective in improving skin tone, texture and appearance.
» More Articles for LFVN

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
Events for the Week of Sept. 15-19th Sep 16 2014 - BENZINGA

More From Other Websites
LIFEVANTAGE CORP Files SEC form 8-K, Regulation FD Disclosure Sep 18 2014
LIFEVANTAGE CORP Financials Sep 17 2014
LifeVantage Announces New Strategic Sales Initiative Targeting the More Than 80 Million Millennials... Sep 11 2014
LifeVantage Corp Earnings Call scheduled for 4:30 pm ET today Sep 10 2014
LIFEVANTAGE CORP Files SEC form 8-K, Results of Operations and Financial Condition Sep 10 2014
LIFEVANTAGE CORP Files SEC form 10-K, Annual Report Sep 10 2014
LifeVantage Announces Fourth Quarter and Full Fiscal Year 2014 Results Sep 10 2014
Q4 2014 LifeVantage Corp Earnings Release - After Market Close Sep 10 2014
LifeVantage to Present at the Imperial Capital Global Opportunities Conference Sep 08 2014
Coverage initiated on Lifevantage by Midtown Partners Sep 08 2014
LIFEVANTAGE CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 27 2014
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2014 Results on September 10, 2014 Aug 26 2014
LIFEVANTAGE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 05 2014
LifeVantage Announces Preliminary Fourth Quarter and Full Fiscal 2014 Results Aug 05 2014
Herbalife: MLM-Legal Fiction, Economic Fallacy, And Marketing Miracle Jun 23 2014
LIFEVANTAGE CORP Files SEC form 8-K, Other Events Jun 16 2014
LIFEVANTAGE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Jun 03 2014
LIFEVANTAGE CORP Files SEC form 8-K, Change in Directors or Principal Officers May 28 2014
Best Stocks Under $5 Right Now May 15 2014
LifeVantage's (LFVN) CEO Doug Robinson on Q3 2014 Results - Earnings Call Transcript May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK